Abstract: This method comprises: depending on the Hb, MCV and CRP values of blood samples, eliminating blood samples derived from subjects with inflammatory anemia; and, depending on the serum ferritin values of the remaining blood samples (A1), determining whether the blood samples (A1) are blood samples that are derived from subjects with hypoferric anemia or blood samples (A2) that are derived from subjects with thalassemia.
| # | Name | Date |
|---|---|---|
| 1 | 202317040120-STATEMENT OF UNDERTAKING (FORM 3) [12-06-2023(online)].pdf | 2023-06-12 |
| 2 | 202317040120-PROOF OF RIGHT [12-06-2023(online)].pdf | 2023-06-12 |
| 3 | 202317040120-PRIORITY DOCUMENTS [12-06-2023(online)].pdf | 2023-06-12 |
| 4 | 202317040120-FORM 1 [12-06-2023(online)].pdf | 2023-06-12 |
| 5 | 202317040120-FIGURE OF ABSTRACT [12-06-2023(online)].pdf | 2023-06-12 |
| 6 | 202317040120-DRAWINGS [12-06-2023(online)].pdf | 2023-06-12 |
| 7 | 202317040120-DECLARATION OF INVENTORSHIP (FORM 5) [12-06-2023(online)].pdf | 2023-06-12 |
| 8 | 202317040120-COMPLETE SPECIFICATION [12-06-2023(online)].pdf | 2023-06-12 |
| 9 | 202317040120-ENDORSEMENT BY INVENTORS [14-06-2023(online)].pdf | 2023-06-14 |
| 10 | 202317040120.pdf | 2023-06-16 |
| 11 | 202317040120-FORM-26 [01-09-2023(online)].pdf | 2023-09-01 |
| 12 | 202317040120-FORM 3 [04-12-2023(online)].pdf | 2023-12-04 |
| 13 | 202317040120-FORM 18 [06-06-2024(online)].pdf | 2024-06-06 |